Paul Gilreath, MD
Neurology · Jasper, ALNPI 1124229117
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 620 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.
Across 620 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Supernus Pharmaceuticals, Inc.$984
- Boston Scientific$716
- AbbVie$596
- SK Life Science, Inc.$430
- Teva Pharmaceuticals USA, Inc.$403
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$460%
- Food & beverage$9,06998%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 144 | $1,962 |
| Supernus Pharmaceuticals, Inc. | 81 | $984 |
| Boston Scientific | 71 | $716 |
| AbbVie(2 entities) | 41 | $596 |
| SK Life Science, Inc. | 25 | $430 |
| Teva Pharmaceuticals USA, Inc. | 19 | $403 |
| Adamas Pharmaceuticals, Inc. | 24 | $373 |
| Lilly USA, LLC | 25 | $373 |
| Eisai Inc. | 21 | $322 |
| Jazz Pharmaceuticals Inc. | 18 | $318 |
| Pfizer | 15 | $295 |
| Biohaven Pharmaceuticals, Inc. | 22 | $281 |
| Amgen | 14 | $278 |
| Lundbeck LLC | 10 | $244 |
| CSL Behring | 9 | $214 |
| Sunovion Pharmaceuticals Inc. | 12 | $199 |
| AstraZeneca | 8 | $164 |
| Harmony Biosciences LLC | 7 | $135 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $99 |
| Neurelis, Inc. | 4 | $91 |
| Kyowa Kirin, Inc. | 3 | $76 |
| Arbor Pharmaceuticals, Inc. | 5 | $72 |
| EMD Serono, Inc. | 4 | $70 |
| Amneal Pharmaceuticals LLC | 3 | $59 |
| Neurocrine Biosciences, Inc. | 2 | $49 |
| Novartis | 3 | $49 |
| Assertio Therapeutics, Inc. | 3 | $49 |
| Acadia Pharmaceuticals Inc | 3 | $48 |
| Acorda Therapeutics, Inc | 3 | $46 |
| Averitas Pharma Inc. | 2 | $36 |
| Biogen | 2 | $30 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| MDD US Operations, LLC | 2 | $28 |
| Almatica Pharma LLC | 2 | $28 |
| Merck | 2 | $27 |
| Sanofi | 1 | $22 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
How this compares
$9,226 in reported general payments places this provider in the 65th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Propranolol Hcl ErPropranolol Hcl | 13 | $428 |
| Gabapentin | 25 | $347 |
| Amitriptyline Hcl | 11 | $61 |
Paid to pharmacies, not to this prescriber.
Other neurology in Jasper
- Diane CounceBirmingham$895K
- Daniel DeesMobile$799K
- Christopher LagankeCullman$711K
- Hayden LongMobile$386K
- Harry McDarisHuntsville$307K
- Belinda Savage-EdwardsHuntsville$296K
- Emily RiserBirmingham$231K
- Nojan ValadiOpelika$219K
- Charles MarkleMobile$212K
- Timothy PrestleyTuscaloosa$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.